Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Anil Sood is a Professor at the University of Texas M D Anderson Cancer Center, United States. His research focuses on cancer biology, particularly in the areas of ovarian cancer, tumor biomarkers, and the impact of genetic mutations on treatment outcomes. Recent publications include studies on caregiver burden in ovarian cancer, the role of immune microenvironments, and the potential of novel markers for liquid biopsies in cancer management.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (7)

David Gershenson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jeffrey How

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ningyan Zhang

University of Texas Medical School at Houston

UNITED STATES

View details

R. Tyler Hillman

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Cayla Zandbergen

Assistant Professor

University of New Mexico

UNITED STATES

View details

Jinsong Liu

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Kwong-Kwok Wong

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anil Sood

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors

Caregiver burden and risk of epithelial ovarian cancer in the Nurses’ Health Studies

EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

Spatiotemporal view of malignant histogenesis and macroevolution via formation of polyploid giant cancer cells

Antibody therapeutics for epithelial ovarian cancer

Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression

Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles

Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status

IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming

Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates

Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer

Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity

Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum

Collaborators (7)

David Gershenson

Jeffrey How

Ningyan Zhang

R. Tyler Hillman

Cayla Zandbergen

Jinsong Liu

Kwong-Kwok Wong

Make your next move.